Trials / Withdrawn
WithdrawnNCT05053308
Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement
Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement Versus Intravenous PCA for Breakthrough Cancer Pain: A Prospective, Randomized, Open Label, Non Inferiority Trial
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Seoul National University · Academic / Other
- Sex
- All
- Age
- 19 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Proportional dose of sublingual fentanyl tablet (Narco®) based on daily opioid requirement versus intravenous PCA for breakthrough cancer pain: A prospective, randomized, open-label, noninferiority trial.
Detailed description
Based on the previous around-the-clock analgesic demand compared to IV PCA in cancer pain patients to prepare the basis for the administration of fentanyl sublingual tablets with an initial dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Intravenous Infusion | IV PCA(fentanyl) Fentanyl bolus = MME \* 15% |
| DRUG | Sublingual Tablet | subligual fentanyl(Narco®) Fentanyl 100mcg/200mcg/300mcg according to the around-the-clock opioid requirement. |
Timeline
- Start date
- 2022-12-01
- Primary completion
- 2023-05-31
- Completion
- 2023-12-31
- First posted
- 2021-09-22
- Last updated
- 2023-08-07
Source: ClinicalTrials.gov record NCT05053308. Inclusion in this directory is not an endorsement.